Literature DB >> 14512821

Realistic expectations: the management of severe Alzheimer disease.

Roger Bullock1, Gerry Hammond.   

Abstract

Alzheimer disease (AD) is a progressive neurodegenerative disorder characterized by a loss of memory and cognition, a decline in ability to perform activities of daily living, changes in personality and behavior, and an increase in resource utilization and medical care. The natural course of AD can be viewed as a gradual loss of independence divided into several stages (mild, moderate, and severe) that ultimately leaves the patient under the supervision of a caregiver. Acetylcholinesterase inhibitors are the most widely accepted and proven approach to the treatment of mild to moderate AD. However, management of patients with severe AD poses challenges to physicians because there are only limited treatment options for these patients. This article provides overviews of the natural history, current therapy, and diagnostic scales of AD, focusing on management of patients with severe AD. In addition, a brief summary of the existing clinical trials conducted in severe AD is presented.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14512821     DOI: 10.1097/00002093-200307003-00004

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  10 in total

Review 1.  Neuropsychological differences between frontotemporal dementia and Alzheimer's disease: a review.

Authors:  Michal Harciarek; Krzysztof Jodzio
Journal:  Neuropsychol Rev       Date:  2005-09       Impact factor: 7.444

Review 2.  Dependence as a unifying construct in defining Alzheimer's disease severity.

Authors:  Trent McLaughlin; Howard Feldman; Howard Fillit; Mary Sano; Frederick Schmitt; Paul Aisen; Christopher Leibman; Lisa Mucha; J Michael Ryan; Sean D Sullivan; D Eldon Spackman; Peter J Neumann; Joshua Cohen; Yaakov Stern
Journal:  Alzheimers Dement       Date:  2010-11       Impact factor: 21.566

3.  Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective.

Authors:  Roy W Jones; Paul McCrone; Chantal Guilhaume
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 4.  What are the treatment options for patients with severe Alzheimer's disease?

Authors:  Thierry Voisin; Emma Reynish; Florence Portet; Howard Feldman; Bruno Vellas
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

5.  Cost effectiveness of memantine in moderately severe to severe Alzheimer's disease : a markov model in Finland.

Authors:  Clément François; Harri Sintonen; Raimo Sulkava; Benoît Rive
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

6.  Cognitive decline and dementia in the oldest-old.

Authors:  Efrat Kravitz; James Schmeidler; Michal Schnaider Beeri
Journal:  Rambam Maimonides Med J       Date:  2012-10-31

7.  Validity and reliability of the persian version of lawton instrumental activities of daily living scale in patients with dementia.

Authors:  Afsoon Hassani Mehraban; Yasamin Soltanmohamadi; Malahat Akbarfahimi; Ghorban Taghizadeh
Journal:  Med J Islam Repub Iran       Date:  2014-05-03

8.  Ability to perform activities of daily living is the main factor affecting quality of life in patients with dementia.

Authors:  Christian K Andersen; Kim U Wittrup-Jensen; Anette Lolk; Kjeld Andersen; Per Kragh-Sørensen
Journal:  Health Qual Life Outcomes       Date:  2004-09-21       Impact factor: 3.186

9.  Cellular stress response, redox status, and vitagenes in glaucoma: a systemic oxidant disorder linked to Alzheimer's disease.

Authors:  Angela Trovato Salinaro; Carolin Cornelius; Guido Koverech; Angela Koverech; Maria Scuto; Francesca Lodato; Vincenzo Fronte; Vera Muccilli; Michele Reibaldi; Antonio Longo; Maurizio G Uva; Vittorio Calabrese
Journal:  Front Pharmacol       Date:  2014-06-06       Impact factor: 5.810

10.  Telemedicine for the management of neuropsychiatric symptoms in long-term care facilities: the DETECT study, methods of a cluster randomised controlled trial to assess feasibility.

Authors:  Antoine Piau; Fati Nourhashemi; Adélaïde De Mauléon; Achille Tchalla; Claude Vautier; Bruno Vellas; Maryline Duboue; Nadège Costa; Pierre Rumeau; Benoit Lepage; Maria Soto Martin
Journal:  BMJ Open       Date:  2018-06-12       Impact factor: 2.692

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.